glp-1 approved for pcos Rising use of medications among women with GLP-1 medications emerging as PCOS

doi: 10.2337/dci23-0100 [DOI] [PubMed] [Google Scholar] 31.Jensen SB, Blond MB, Sandsdal RS, et al

Another meta-analysis of large cardiovascular outcome trials such as SUSTAIN ( injectable semaglutide ), LEADER ( liraglutide ), HARMONY ( albiglutide ) (Hernandez et al., 2018), ELIXA ( lixisenatide ) (Pfeffer et al., 2015) and EXSCEL ( exenatide ) (Holman et al., 2017) appeared to reduce the risk of total stroke (by, i.e

Retatrutide contribution includes improved insulin sensitivity (GLP-1 and GIP), reduced liver fat (glucagon), improved lipid profiles (all three receptors), and reduced blood pressure (weight loss effect)

This can make you more prone to infections and chronic inflammatory conditions